Pretreatment plasma sCD14 as a prognostic indicator in advanced non-small cell lung cancer patients undergoing immunotherapy
sCD14 is a promising prognostic biomarker for aNSCLC patients undergoing immunotherapy. Elevated plasma sCD14 levels are associated with improved PFS and a favorable immune response.
Authors
- Xiaohong Han (ORCID: https://orcid.org/0000-0001-9190-0167)
- Lin Li (ORCID: https://orcid.org/0000-0001-6980-139X)
- Le Tang (ORCID: https://orcid.org/0000-0002-5192-3329)
- Liling Huang (ORCID: https://orcid.org/0000-0002-5023-8370)
- Jiarui Yao (ORCID: https://orcid.org/0000-0002-9835-395X)
- Yuankai Shi (ORCID: https://orcid.org/0000-0002-8685-6744)
- Liyuan Dai (ORCID: https://orcid.org/0009-0007-4848-3709)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1186/s12885-025-14148-2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences
- Peking Union Medical College Hospital